| Thomas Fuchs |
Thomas Fuchs currently works at GeneDx Holdings Corp., as Director from 2025 and Eli Lilly & Co., as Chief Artificial Intelligence Officer & Senior VP. Dr. Fuchs received his doctorate degree from Swiss Federal Institute of Technology and graduate degree from Graz University of Technology. |
| Lucas E. Montarce |
Lucas E. Montarce currently works at Christel House International, Inc., as Director, Eli Lilly & Co., as Chief Financial Officer & Executive Vice President from 2024, and Lilly Research Laboratories, as Chief Financial Officer, Group VP & Controller from 2021. Mr. Montarce also formerly worked at Elanco Animal Health, Inc., as Chief Financial Officer in 2018. Mr. Montarce received his undergraduate degree from The Catholic University of America and Masters Business Admin degree from Universidad del CEMA. |
| David Hyman |
Dr. David Hyman, MD, is a Chief Medical Officer at Eli Lilly & Co. and a Chief Medical Officer at Loxo Oncology, Inc. |
| Eric Dozier |
Eric Dozier currently works at Christian Theological Seminary, Inc., as Director, Center for Leadership Development, Inc., as Director, Indianapolis Airport Authority (Indiana), as Director, and Eli Lilly & Co., as Chief People Officer & Executive Vice President from 1998. Mr. Dozier received his Masters Business Admin degree from Indiana University and undergraduate degree from The Ohio State University. |
| Diogo Rau |
Diogo Rau is the founder of GiftGateway, founded in 1999. Mr. Rau is currently employed at Eli Lilly & Co. as Executive VP, Chief Information & Digital Officer since 2021. Former positions include Senior Director-Information Systems & Technology at Apple, Inc. from 2011 to 2021 and Partner at McKinsey & Co., Inc. from 2003 to 2011. Education includes undergraduate and graduate degrees from Stanford University. |
| Patrik Jonsson |
Patrik Jonsson currently works at Eli Lilly & Co., as Executive VP & President-Lilly International from 2025. Mr. Jonsson also formerly worked at The American Chamber of Commerce in Japan, as Director, Eli Lilly Italia SpA, as President & General Manager, and Lilly USA LLC, as President. Mr. Jonsson received his undergraduate degree from Lund University School of Economics & Management. |
| David A. Ricks |
Mr. David A. Ricks is an Independent Director at Adobe, Inc., a Chairman, President & Chief Executive Officer at Eli Lilly & Co., a Chairman & Chief Executive Officer at Eli Lilly & Co. Ltd., a Chairman & Chief Executive Officer at Eli Lilly Italia SpA, a Chairman-Governors Board at James Whitcomb Riley Children's Foundation, a Member at The Business Council and a Member at The Business Roundtable. He is on the Board of Directors at Adobe, Inc., Pharmaceutical Research & Manufacturers of America and The Central Indiana Corporate Partnership. Mr. Ricks was previously employed as a President by Lilly USA LLC, a President & General Manager by Lilly Industries Shanghai Ltd., a General Manager by Eli Lilly Canada, Inc., a Principal by HP, Inc., a Principal by International Business Machines Corp., and a President by International Federation of Pharmaceutical Manufacturers. He also served on the board at Elanco Animal Health, Inc. and European Federation of Pharmaceutical Industries & Assns. He received his undergraduate degree from Purdue University and an MBA from Indiana University. |
| Donald A. Zakrowski |
Donald A. Zakrowski currently works at Eli Lilly & Co., as Chief Accounting Officer & Vice President-Finance from 2012. Mr. Zakrowski also formerly worked at PricewaterhouseCoopers LLP, as Senior Manager. |
| Daniel M. Skovronsky |
Daniel M. Skovronsky was the founder of Avid Radiopharmaceuticals, Inc., founded in 2004, where the title held was Chief Executive Officer. Current jobs include Independent Director at Myriad Genetics, Inc. since 2020; Chief Scientific Officer & Executive Vice President at Eli Lilly & Co. starting in 2024; Member at the University of Pennsylvania; Member-Governance Board at Indianapolis Museum of Art, Inc.; and President, Chief Scientific Officer & Senior Vice President at Lilly Research Laboratories since 2018. Education history includes a doctorate from the University of Pennsylvania conferred in 2000, an undergraduate degree from Yale University conferred in 1994, and a doctorate from Perelman School of Medicine conferred in 2001. |
| Edgardo Hernandez |
Edgardo Hernandez is currently working as the President-Manufacturing Operations & Senior VP at Eli Lilly & Co. He started this position in 2021. Prior to his current role, he obtained a graduate degree from North Carolina State University and an undergraduate degree from the University of Puerto Rico. |
| Jacob S. van Naarden |
Jacob S. van Naarden is Chief Executive Officer at Loxo Oncology, Inc. since 2014. He is Director at Delfi Diagnostics, Inc. since 2022. He is President-Lilly Oncology & Executive Vice President at Eli Lilly & Co. since 2024. Formerly, Mr. van Naarden was an Analyst at HealthCor Management LP from 2013 to 2014. He was an Associate at Aisling Capital LLC from 2008 to 2013. He worked as an Analyst at Goldman Sachs & Co. LLC from 2006 to 2008. Mr. van Naarden completed undergraduate studies at Princeton University in 2006. |
| Katherine Baicker |
Katherine Baicker currently works at Eli Lilly & Co., as Independent Director from 2011, Mayo Clinic, as Trustee from 2019, Council on Foreign Relations, Inc., as Member, American Academy of Arts & Sciences, as Member, National Academy of Medicine (United States), as Member, National Bureau of Economic Research, Inc., as Research Associate, The Chicago Council on Global Affairs, as Trustee, National Opinion Research Center, as Trustee, National Academy of Social Insurance, as Member, The University of Chicago Harris School of Public Policy, as Dean & Professor from 2017, and Harris School of Public Policy Studies, as Dean from 2017. Dr. Baicker also formerly worked at National Institutes of Health, as Chairman-Social Sciences & Population Study, AcademyHealth, as Vice Chairman, The Group Insurance Commission, as Chairman, HMS Holdings Corp., as Independent Director from 2019 to 2021, Dartmouth College, as Associate Professor & Assistant Professor from 1998 to 2005, The Urban Institute, as Trustee, Council of Economic Advisers, as Member from 2005 to 2007, Harvard T.H. Chan School of Public Health, as Professor-Health Economics from 2007 to 2017, and Health Affairs, as Member-Editorial Board. Dr. Baicker received her doctorate degree in 1998 from Harvard University and undergraduate degree in 1993 from Yale University. |
| Mary Lynne Hedley |
Mary Lynne Hedley founded Zycos, Inc. in 1996, where she worked as President & Chief Executive Officer from 1996 to 2004 and Tesaro, Inc. in 2010, where she is working as President & Director. Dr. Hedley also currently works at Eli Lilly & Co., as Independent Director from 2022, Veeva Systems, Inc., as Independent Director from 2019, Millendo Therapeutics US, Inc., as Director from 2017, Helsinn Holding SA, as Director from 2021, Youville Place, as Director, Centessa Pharmaceuticals Plc, as Independent Non-Executive Director from 2021, Women Innovating Together In Healthcare, as Director, Youville Assisted Living Residences, as Director, Third Rock Ventures LLC, as Venture Partner from 2023, The American Association of Immunologists, as Member, American Association for the Advancement of Science, as Member, American Society of Clinical Oncology, Inc., as Member, and The American Association of Cancer Research, as Member. Dr. Hedley also formerly worked at Receptos LLC, as Independent Director from 2014 to 2015, bluebird bio, Inc., as Independent Director from 2017 to 2019, Millendo Therapeutics, Inc., as Independent Director from 2017 to 2021, Helsinn Healthcare SA, as Director from 2021 to 2023, MGI PHARMA, Inc., as Chief Scientific Officer & Executive VP from 2004 to 2008, Abraxis BioScience, Inc., as Chief Scientific Officer & EVP-Operations from 2009 to 2010, Eisai Corp. of North America, as Executive Vice President from 2008 to 2009, and MGI PHARMA Biologics, Inc., as General Manager & Senior Vice President. Dr. Hedley received her undergraduate degree in 1983 from Purdue University and doctorate degree in 1988 from The University of Texas Southwestern Medical Center. |
| Ralph Alvarez |
Mr. Ralph Alvarez is a Lead Independent Director at Traeger, Inc., an Independent Chairman at First Watch Restaurant Group, Inc., an Independent Director at Lowe's Companies, Inc., an Independent Director at Eli Lilly & Co. and a Member-Presidents Council at University of Miami School of Business. He is on the Board of Directors at Traeger, Inc., Lowe's Companies, Inc. and Eli Lilly & Co. Mr. Alvarez was previously employed as an Independent Director by Realogy Holdings Corp. (NJ), an Executive Chairman by Skylark Co. Ltd. /Old/, a Chairman by Skylark Co., Ltd., a Lead Independent Director by Dunkin' Brands Group, Inc., a President by McDonald’s North America, a President by McDonald's Mexico, a COO & President-Central Division by McDonald's USA LLC, a Regional Director by Chipotle Mexican Grill, Inc., a President, Chief Operating Officer & Director by McDonald's Corp., a Vice President by Wendy’s International, Inc., a Budget Analyst by Burger King Corp., a Partner by Advent International LP, a Managing Director by Burger King España SL, a President by Burger King Restaurants of Canada, Inc., a President by Ronald McDonald House Charities Central West, and a Trustee by The Field Museum of Natural History. He also served on the board at Anywhere Real Estate Group LLC, Dunkin' Brands, Inc., KeyCorp, Fox Cities Performing Arts Center, Inc., National Retail Federation, Inc. and The Presidents Council. He received his undergraduate degree from the University of Miami. |
| Gabrielle G. Greene-Sulzberger |
Gabrielle G. Greene-Sulzberger founded Fontis Partners LP in 2009, where she worked as General Partner from 2009 to 2017. Ms. Greene-Sulzberger also currently works at Sesame Workshop, as Chairman, True Food Kitchen Investco LLC, as Chairman from 2019, auxmoney GmbH, as Chairman, and various other companies. Ms. Greene-Sulzberger also formerly worked at Johnson Products Co., Inc., as Chief Executive Officer from 2011 to 2013, Teneo Holdings LLC, as Chairman-ESG Practice, Teneo Consulting LLC, as Chairman-ESG Practice, and various other companies. Ms. Greene-Sulzberger received her Masters Business Admin degree in 1987 from Harvard Business School, graduate degree from Harvard Law School, and undergraduate degree from Woodrow Wilson School of Public & International Affairs. |
| Carolyn R. Bertozzi |
Carolyn R. Bertozzi founded Redwood Bioscience, Inc. in 2008, Palleon Pharmaceuticals, Inc. in 2015, Venn Biosciences Corp. in 2017, and Lycia Therapeutics, Inc. in 2019. Dr. Bertozzi also founded Firefly Bio, Inc. and Enable Biosciences, Inc., where she is working as Chairman. Dr. Bertozzi also currently works at Grace Science Foundation, as Director, OmniAb Operations, Inc., as Independent Director, OmniAb, Inc., as Independent Director from 2022, Stanford Chem-H, as Director from 2021, Xaira Therapeutics, Inc., as Director, Eli Lilly & Co., as Director from 2025, Stanford University, as Professor, American Chemical Society, as Member, The Royal Society, as Member, Howard Hughes Medical Institute, Inc., as Professor, National Academy of Sciences, as Member, American Academy of Arts & Sciences, as Member, National Academy of Medicine (United States), as Member, American Society for Biochemistry & Molecular Biology, Inc., as Member, Accademia Nazionale dei Lincei, as Member, and National Academy of Inventors, as Member. Dr. Bertozzi also formerly worked at Eli Lilly & Co., as Independent Director from 2017 to 2021, Lawrence Berkeley National Laboratory, as Director-Molecular Foundry, The Broad Institute, Inc., as Director, Catalent, Inc., as Director, Molecular Foundry, as Director, Alnylam Pharmaceuticals, Inc., as Independent Director from 2023 to 2025, and the University of California, Berkeley, as Professor from 1996 to 2015. Dr. Bertozzi received her undergraduate degree in 1988 from Harvard University and doctorate degree in 1993 from the University of California, Berkeley. |
| Jamere Jackson |
Jamere Jackson is currently an Independent Director at Eli Lilly & Co. since 2016, a Director at Azaa Investments, Inc., Youth Villages, Inc., and Future 5, and the Chief Financial Officer at AutoZone, Inc. since 2023. Former positions include Independent Director at Hibbett, Inc. from 2020 to 2022; Chief Financial Officer and Executive Vice President at The Hertz Corp. and Hertz Global Holdings, Inc. from 2018 to 2020; Chief Financial Officer at Nielsen Holdings Ltd. from 2014 to 2018; VP, Chief Financial Officer-Drilling & Surface at Baker Hughes Energy Services LLC from 2013 to 2014; Senior Executive-Finance at GE Aviation Systems LLC from 2007 to 2013; Principal at GE Aerospace from 2004 to 2014; and Principal roles at First Data Corp., Procter & Gamble Co., Total System Services LLC, Yum! Brands, Inc., and The Nielsen Company (US) LLC. Other former roles include Chief Financial Officer at Nielsen NV and. The Nielsen Co. BV, Treasurer at Unison Industries LLC. Education includes an undergraduate degree from the University of Notre Dame, conferred in 1990. |
| Jon Erik Fyrwald |
Jon Erik Fyrwald is Chief Executive Officer & Director at International Flavors & Fragrances, Inc. since 2024. Holds CEO roles at Syngenta Crop Protection –. Soluções Para A Agricultura, Ltda., Syngenta Foundation For Sustainable Agriculture (Chairman & CEO), Syngenta Bangladesh Ltd. (CEO & Director), and Syngenta International AG (CEO & Director since 2016). Chairman of ADAMA Ltd. since 2020. Independent Director at Eli Lilly & Co. since 2005. Director at Biotechnology Innovation Organization, Syngenta AG, ADAMA Agricultural Solutions Ltd. (since 2022), Society of Chemical Industry, The Chicago Public Education Fund, CropLife International, Syngenta Crop Protection AG (since 2023), Syngenta Group Co., Ltd. (since 2023), and Trustee at The Field Museum of Natural History since 2010. Former roles include Chairman, President & CEO at Nalco Co. and Nalco Holding Co. (2008–2011), President & CEO at Univar NV, Univar Solutions UK Ltd., Univar Solutions USA, Inc. (Illinois), and Univar Solutions, Inc. (2012–2016). Chairman at Sinofert Holdings Ltd. (2020–2023). Chairman-Management & Member-Management Director at Syngenta AG. Independent Director at Bunge Ltd. (2018–2023). Group VP-Agriculture & Nutrition Division at EIDP, Inc. (2003–2008). President at Ecolab, Inc. (2011–2012). Director roles at Amsted Industries, Inc., 8th Continent LLC, American Chemistry Council, Inc., Edmundson Art Foundation, Inc., United Way of Central Iowa, World Food Programme, and Swiss-American Chamber of Commerce. Education includes an undergraduate degree from the University of Delaware, conferred in 1981. |
| Juan Ricardo Luciano |
Juan Ricardo Luciano currently works at Archer-Daniels-Midland Co., as Chairman, President & Chief Executive Officer from 2016, Eli Lilly & Co., as Lead Independent Director from 2019, Rush System for Health, as Director, The Business Council, as Director, ADM Grain River System, Inc., as Director from 2012, ADM Clinton BioProcessing, Inc., as Director from 2012, Intersect Illinois, as Director, The Commercial Club of Chicago, as Member, The Business Roundtable, as Member, Dow Hydrocarbons & Resources LLC, as Member, Global Advisory Board, as Member from 2017, and The Economic Club of Chicago, as Member. Mr. Luciano also formerly worked at ADM Alliance Nutrition, Inc., as Director, Wilmar International Ltd., as Non-Executive Director from 2012 to 2022, The Economic Club of Chicago (Illinois), as Director, Kellogg School of Management, as Director, The Dow Chemical Co., as President-Performance Division from 2010 to 2011, Boys & Girls Clubs of America, as Trustee, Rush University Medical Center, as Trustee, and US-China Business Council, as Member. Mr. Luciano received his undergraduate degree from Instituto Tecnológico de Buenos Aires. |
| Jon R. Moeller |
Jon R. Moeller currently works at Procter & Gamble Co., as Chairman, President & Chief Executive Officer from 2022, Procter & Gamble Service GmbH, as Chairman, President & Chief Executive Officer, Procter & Gamble (Manufacturing) Ireland Ltd., as Chief Operating Officer, CFO & Vice Chairman, MDVIP LLC (Florida), as Director, Natura Pet Products, Inc., as Director, The Consumer Goods Forum, as Director, Isle of Harris Distillers Ltd., as Director, Alliance To End Plastic Waste, as Director, The Business Roundtable, as Director, Eli Lilly & Co., as Independent Director from 2024, Commercial Club of Cincinnati, as Trustee, Cincinnati Art Museum, as Vice President, and The Conference Board Council of Financial Executives, as Member. Mr. Moeller also formerly worked at Monsanto Co., as Independent Director from 2011 to 2018 and Visiting Nurse Association, as Trustee. Mr. Moeller received his undergraduate degree in 1986 and Masters Business Admin degree in 1988 from Cornell University. |
| Kimberly H. Johnson |
Kimberly H. Johnson currently works at Eli Lilly & Co., as Independent Director from 2021, Greater Washington Board of Trade, as Director, Share Our Strength, Inc., as Director, Calvert Impact Capital, Inc., as Director, After-School All-Stars, as Director, Planet Works, Inc., as Director, Communities In Schools of The Nations Capital, as Director, T. Rowe Price Group, Inc., as Chief Operating Officer from 2022, and Princeton University, as Trustee. Ms. Johnson also formerly worked at Credit Suisse Group AG, as Director, Credit Suisse (USA) LLC, as Director, Federal National Mortgage Association, as Chief Operating Officer & Executive Vice President from 2018 to 2022, and D.E. Shaw & Co. LLC, as Equity Trader. Ms. Johnson received her undergraduate degree from Princeton University and Masters Business Admin degree from Columbia Business School. |
| William G. Kaelin |
William G. Kaelin is the founder of Tango Therapeutics Sub, Inc. (founded in 2017), Cedilla Therapeutics, Inc. (founded in 2017), and Tango Therapeutics, Inc. (founded in 2017). Current jobs include Independent Director at Eli Lilly & Co. since 2012, Director at The Damon Runyon Cancer Research Foundation, Director at LifeMine Therapeutics, Inc. since 2021, Director at IconOVir Bio, Inc. since 2022, Independent Director at IQVIA Holdings, Inc. starting 2025, Trustee at Duke University, Professor at Dana-Farber Cancer Institute, Inc., Professor at The Brigham & Women's Hospital, Inc. since 2002, Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the Association of American Physicians, Member of Dana-Farber, Member of the American Society of Clinical Investigation, Professor at Harvard Medical School since 2002, and Advisor at Casdin Capital. Former jobs include Chief Resident & House Officer at The Johns Hopkins Hospital, Inc., Member-Advisory Board at National Cancer Institute, Member of the National Academy of Medicine (United States), Member of the American College of Physicians, Inc., and Trustee of the American Association for Cancer Research. Education includes undergraduate degree from Duke University in 1982 and a doctorate from Duke University School of Medicine. |
